Sign In
Buy RARE
$22.41
+0.630 (+2.89%)
At Close: Jun 03, 2026
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
02:51pm, Thursday, 21'st Aug 2025
NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Suc
Company expects to complete BLA submission in the fourth quarter of 2025 Company expects to complete BLA submission in the fourth quarter of 2025
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
11:43am, Sunday, 17'th Aug 2025
NEW YORK, Aug. 17, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Suc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
10:00am, Saturday, 16'th Aug 2025
NEW YORK , Aug. 16, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
11:43am, Wednesday, 13'th Aug 2025
NEW YORK, Aug. 13, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Suc
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
10:00am, Monday, 11'th Aug 2025
NEW YORK , Aug. 11, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
12:25pm, Saturday, 09'th Aug 2025
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. (“Ultragenyx” or the “Company”) (NASDAQ: RARE). Suc
Ultragenyx's Q2 Loss Narrower Than Expected, Revenues Rise Y/Y
12:45pm, Wednesday, 06'th Aug 2025
RARE posts a narrower Q2 loss and 13% revenue growth as demand rises across all four marketed rare disease drugs.
Ultragenyx (RARE) Q2 Revenue Up 13%
10:59am, Wednesday, 06'th Aug 2025
Ultragenyx (RARE) Q2 Revenue Up 13%
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
10:00am, Wednesday, 06'th Aug 2025
NEW YORK , Aug. 6, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investors
Ultragenyx Pharmaceutical Inc. (RARE) Q2 2025 Earnings Call Transcript
12:42am, Wednesday, 06'th Aug 2025
Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE ) Q2 2025 Earnings Conference Call August 5, 2025 5:00 PM ET Company Participants Emil D. Kakkis - Founder, President, CEO & Director Eric Crombez - Chief M
Ultragenyx (RARE) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
06:31pm, Tuesday, 05'th Aug 2025
Although the revenue and EPS for Ultragenyx (RARE) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Stree
Ultragenyx Reports Second Quarter 2025 Financial Results and Corporate Update
04:01pm, Tuesday, 05'th Aug 2025
Second quarter total revenue of $166 million, Crysvita® revenue of $120 million and Dojolvi® revenue of $23 million
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc. - RARE
10:00am, Thursday, 31'st Jul 2025
NEW YORK , July 31, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. ("Ultragenyx" or the "Company") (NASDAQ: RARE). Such investor
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update
08:30am, Wednesday, 30'th Jul 2025
NOVATO, Calif., July 30, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for seri
